MedPath

Tumor-specific T Cells in Lung Cancer

Not Applicable
Active, not recruiting
Conditions
Non-small Cell Lung Cancer
Registration Number
NCT02515760
Lead Sponsor
University Hospital Heidelberg
Brief Summary

Non-small cell lung cancer is characterized by aggressive growth and treatment resistance. New approaches include immunotherapeutic strategies but spontaneous immune responses against tumor antigens remain unclear. The aim of this study is to characterize localization and frequencies of spontaneously induced memory T cells specific for a panel of tumor-associated antigens in peripheral blood and bone marrow of non-small cell lung cancer patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Patients with histology proven non-small cell lung cancer or a lesion suspicious of non-small cell lung cancer (lung cancer group)
  • Healthy donors (control group)
  • written informed consent
Exclusion Criteria
  • Autoimmune disease
  • Patients receiving immunomodulatory drugs, e.g. tacrolimus
  • Prior malignancy
  • Pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Frequencies of tumor-specific T cells2 weeks postoperative

% of all T cells

Secondary Outcome Measures
NameTimeMethod
Long-term survival5 years postoperative

OS

Tumor-specific T cells location determined by Enzyme Linked Immuno Spot Assay (ELISPOT) analysis of peripheral blood and bone marrow samples from the same patient2 weeks postoperative

location: peripheral versus bone marrow

Trial Locations

Locations (1)

Division of Thoracic Surgery, Technical University of Munich, Munich, Germany

🇩🇪

Munich, Germany

Division of Thoracic Surgery, Technical University of Munich, Munich, Germany
🇩🇪Munich, Germany

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.